Fate stock: buy or sell?

FATE stock price: $13.67 0.74% At close on December 6th, 2019

Updated on:
December 6th, 2019

0

Fate closed today at $13.67 and raised a slightly fine 0.74%. On Monday FATE plunged a hair-raising -10.16%.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

Should I buy Fate stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Fate Therapeutics stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean FATE will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Fate Therapeutics stock a buy?

Banks and financial institutions post stock ratings everyday. At Stocks2.com, we gathered 14 ratings published for FATE stock in the last 30 days.

The general sentiment of these ratings is bullish for FATE stock, with 12 positive ratings.
Is FATE a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-4Mizuhon/aBuy
2019-9-16Piper Jaffray Companiesn/aOverweight
2019-8-9BTIG ResearchBuyBuy
2019-7-22Cantor FitzgeraldOverweightOverweight
2019-7-12Oppenheimern/aOutperform
2019-7-12CIBCOutperformOutperform
2019-6-7Roth Capitaln/aNeutral
2019-6-27Piper Jaffray CompaniesOverweightTop Pick
2019-5-24CitigroupBuyBuy
2019-5-24Citigroupn/aBuy
2019-3-6Wells Fargo & Con/aOutperform
2019-3-28Svb Leerinkn/aOutperform
2019-3-28Leerink Swannn/aOutperform
2019-2-11WedbushOutperformOutperform

Fate stock analysis

Daily outlook

Fate shares raised 0.74% to $13.67 today.

Shares of Fate ended today at $13.67 and raised a slightly fine 0.74%. Since price and SMA200d lines crossed down on September, FATE fell $-4.53 per share (-24.89%).

FATE stock chart (daily)

Weekly outlook

After boosting a super good 7.87% in a week last week, Fate Therapeutics closed this week at $13.67 and collapsed a hair-raising -12.48%.

Since price and 40-weeks moving average lines crossed down late September, FATE fell $-4.53 per share (-24.89%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Far behind is the all-time high Fate recorded by mid July and since then the price is -40.10% below that top.

FATE stock chart (weekly)

Fate stock price history

Fate IPO was on October 1st, 2013 at $6.56 per share1. Since then, FATE stock surged a 108.40%, with an average of 18.10% per year. If you had invested right after FATE's IPO a $1,000 in Fate stock in 2013, it would worth $1,084.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Fate stock historical price chart

FATE stock reached all-time highs on July with a price of $22.82.

Fate stock price target is $25.80

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' FATE stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 13 price predictions for Fate stock:
FATE stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-4MizuhoReiteratesn/a$27.00-
2019-9-16Piper Jaffray CompaniesLowers Target$30.00$28.00-6.7%
2019-8-9BTIG ResearchInitiatesn/a$27.00-
2019-7-22Cantor FitzgeraldInitiatesn/a$32.00-
2019-7-12OppenheimerInitiatesn/a$27.00-
2019-7-12CIBCInitiatesn/a$27.00-
2019-6-7Roth CapitalInitiatesn/a$20.00-
2019-6-27Piper Jaffray CompaniesReiterates$23.00$30.0030.4%
2019-5-24CitigroupReiterates$20.00$26.0030%
2019-5-24CitigroupInitiates$20.00$26.0030%
2019-3-6Wells Fargo & CoReiterates$18.00$24.0033.3%
2019-3-28Svb LeerinkInitiatesn/a$20.00-
2019-2-11WedbushRaises Target$19.00$21.0010.5%
(in average)$21.70$25.8019.0%
The price prediction for Fate Therapeutics stock is $25.80, moving in a range between $32.00 and $20.00. In average, analysts' outlook on FATE price target is positive, upgrading the prediction by a 19.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Fate reported tiny results for 2018-Q4 on March. Fate stepped up Earnings per Share (EPS) by 4.20%, beating analysts consensus of $-0.24. Fate posted $-0.25.
FATE earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.24n/a
2017-Q2-n/a-0.23n/a
2017-Q32017-11-01-0.24-0.26n/a
2017-Q42018-03-05-0.24-0.29n/a
2018-Q12018-05-10-0.22-0.27n/a
2018-Q22018-08-06-0.28-0.37n/a
2018-Q32018-11-01-0.24-0.31n/a
2018-Q42019-03-05-0.24-0.25n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Fate Therapeutics annual revenues rocketed an exceptional 15.44% to $4.74 million USD from $4.11 marked in 2017. When comparing 2018 vs 2017, in contrast, profit margin (that is, the net income divided by revenues) plunged a -358.94% to -1,405.02%.

FATE annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$0.97 M-$-20.89 M-2151.4%-
2015$2.43 M150.36%$-29.99 M-1233.7%43.57%
2016$4.40 M81.08%$-33.46 M-760.2%11.57%
2017$4.11 M-6.72%$-42.95 M-1046.1%28.36%
2018$4.74 M15.44%$-66.60 M-1405.0%55.05%

Quarterly financial results

Fate Therapeutics reported $1.66 M in sales for 2018-Q4, a 61.89% up compared to previous quarter. Reported quarter earnings marked $-16.03 M with a profit margin of -964.90%. Profit margin skyrocketed a 670.77% compared to previous quarter when profit margin was -1,635.67%. When comparing turnover to same quarter last year, Fate sales marked an astounding growth and climbed a 61.73%.
FATE quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$1.03 M-$-10.13 M-983.5%-
2017-Q2$1.03 M0.00%$-9.65 M-936.9%-4.74%
2017-Q3$1.03 M0.00%$-10.68 M-1036.9%10.67%
2017-Q4$1.03 M-0.29%$-12.50 M-1216.8%17.01%
2018-Q1$1.03 M-0.10%$-14.14 M-1377.7%13.11%
2018-Q2$1.03 M0.10%$-19.65 M-1913.7%39.04%
2018-Q3$1.03 M-0.10%$-16.78 M-1635.7%-14.61%
2018-Q4$1.66 M61.89%$-16.03 M-964.9%-4.50%

Fate ownership

When you are planning to buy a company, it's worth to review its ownership structure.

Fate shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 2.29% of all shares.

Bearish positions for FATE stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Fate:

FATEBDXIONSNBIXPTCT
Market cap$1.0 B$70.4 B$9.1 B$10.8 B$3.0 B
Total shares75.6 M270.0 M140.7 M92.1 M61.6 M
Float shares63.3 M269.9 M128.0 M90.8 M56.3 M
  - Institutional holdings (%)96.7%87.5%85.9%105.1%85.6%
  - Insider holdings (%)2.3%0.3%9.1%1.3%2.7%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Fate summary

Friday, December 6th, 2019
Open$13.69
Close$13.67
Day range$13.26 - $13.92
Previous close$13.57
Session gain0.74%
Average true range$0.73
50d mov avg$14.63
100d mov avg$16.72
200d mov avg$17.42
Daily patternlt06c
Weekly pattern lt03a

Fate performance

To better understand Fate Therapeutics performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Fate Therapeutics against Becton, Dickinson and, Ionis Pharmaceuticals, Neurocrine Biosciences, PTC Therapeutics and Sarepta Therapeutics in the following table:
Stock3m6m12m
FATEFate Therapeutics-23.55%-24.18%-17.35%
BDXBecton, Dickinson...-0.67%9.70%12.25%
IONSIonis Pharmaceuti...4.50%1.33%21.48%
NBIXNeurocrine Biosci...17.99%41.74%38.76%
PTCTPTC Therapeutics16.64%18.00%48.17%
SRPTSarepta Therapeut...28.31%-11.25%-9.41%

Fate competitors

One check before trading any stock is to review a list of its competitors, in this case for Fate Therapeutics. We chose 5 companies as Fate Therapeutics competitors as they are in the same industry or have similar market objectives.